<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413881</url>
  </required_header>
  <id_info>
    <org_study_id>WRAMC WU # 04-23011</org_study_id>
    <nct_id>NCT00413881</nct_id>
  </id_info>
  <brief_title>A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures</brief_title>
  <official_title>A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to conduct a prospective clinical trial to compare conventional&#xD;
      and WFG LASIK for enhancements on post-LASIK patients. Differences in safety, efficacy,&#xD;
      visual quality, and refractive stability will also be compared during this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Safety 2. Efficacy 3. Refractive stability</measure>
    <time_frame>one year after enhancement</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Refractive Errors</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional LASIK Enhancement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wavefront guided LASIK Enhancement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>WAVEFRONT- GUIDED LASIK ENHANCEMENT</intervention_name>
    <description>Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CONVENTIONAL LASIK ENHANCEMENT</intervention_name>
    <description>Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, of any race, and at least 21 years old at the time of the preoperative&#xD;
             exam, and have signed an informed consent. The lower age limit of 21 years is intended&#xD;
             to ensure documentation of refractive stability.&#xD;
&#xD;
          -  At least 6 months from original LASIK surgery.&#xD;
&#xD;
          -  Stable refraction with more than 0.75D of spherical equivalent from the desired&#xD;
             correction and have less than 1.50D of cylinder in the manifest refraction.&#xD;
&#xD;
          -  Both eyes must be within 1.00D spherical equivalent of each other on the manifest&#xD;
             refraction test.&#xD;
&#xD;
          -  The eye to be treated with wavefront-guided enhancement must have at least a 9.5mm&#xD;
             flap.&#xD;
&#xD;
          -  Manifest refraction and LADARWaveâ„¢ refractions must be within 1.00D.&#xD;
&#xD;
          -  At least 3 lines potential improvement in UCVA.&#xD;
&#xD;
          -  BSCVA of 20/20 or better.&#xD;
&#xD;
          -  Good corneal flap and interface.&#xD;
&#xD;
          -  Adequate corneal thickness for surgery (residual stromal bed &gt; 280 microns).&#xD;
&#xD;
          -  Able and willing to give informed consent.&#xD;
&#xD;
          -  Located in the greater Washington DC area for a 12-month period.&#xD;
&#xD;
          -  Access to transportation to meet follow-up requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding or intend to become pregnant during&#xD;
             the study. Pregnancy will be ruled out with a urine pregnancy test.&#xD;
&#xD;
          -  Concurrent topical or systemic medications that may impair healing, including&#xD;
             corticosteroids, antimetabolites, isotretinoin, amiodarone hydrochloride and/ or&#xD;
             sumatripin, as determined by history.&#xD;
&#xD;
          -  Medical condition(s), which, in the judgement of the investigator, may impair healing,&#xD;
             including but not limited to: collagen vascular disease, autoimmune disease,&#xD;
             immunodeficiency diseases, and ocular herpes zoster or simplex (As determined by&#xD;
             history).&#xD;
&#xD;
          -  Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended&#xD;
             ablation zone, or clinically significant lens opacity.&#xD;
&#xD;
          -  Evidence of glaucoma or an intraocular pressure greater than 22mm Hg at baseline.&#xD;
&#xD;
          -  Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either&#xD;
             eye.&#xD;
&#xD;
          -  Flap irregularity(striae, interface debris, scarring, or epithelium).&#xD;
&#xD;
          -  Calculated residual stroma bed less than 280.&#xD;
&#xD;
          -  Stable refraction with less than 0.75D of spherical equivalent from the desired&#xD;
             correction and more than 1.5D of cylinder in the manifest refraction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RICHARD STUTZMAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center, Center For Refractive Surgery</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <last_update_submitted>January 13, 2010</last_update_submitted>
  <last_update_submitted_qc>January 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2010</last_update_posted>
  <keyword>Residual refractive error left over from initial LASIK correction.</keyword>
  <keyword>Higher Order aberrations measured using a wavefront analyzer.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

